94 related articles for article (PubMed ID: 30026420)
1. [Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
Soshi M; Kawasaki S; Kawamura Y; Watanebe A; Iguchi E; Nishida M; Sakuramachi A; Morita M; Oouchi Y; Nakatsukasa K; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2018 Jun; 45(6):949-954. PubMed ID: 30026420
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.
Ishida N; Araki K; Sakai T; Kobayashi K; Kobayashi T; Fukada I; Hosoda M; Yamamoto M; Ichinokawa K; Takahashi S; Iwase T; Ito Y; Yamashita H
Breast Cancer; 2016 Jul; 23(4):617-23. PubMed ID: 25896598
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yamamoto Y; Ohno S; Toi M
Breast Cancer Res Treat; 2017 Jun; 163(3):545-554. PubMed ID: 28337663
[TBL] [Abstract][Full Text] [Related]
4. Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
Robertson JFR; Steger GG; Neven P; Barni S; Gieseking F; Nolè F; Pritchard KI; O'Malley FP; Simon SD; Kaufman B; Petruzelka L
Ann Oncol; 2010 Jun; 21(6):1246-1253. PubMed ID: 19875750
[TBL] [Abstract][Full Text] [Related]
5. [Assessment of the clinical efficacy and safety of fulvestrant in heavily pretreated patients with hormone-receptor positive metastatic breast cancer-a single-institution experience].
Hattori M; Horio A; Sawaki M; Kondo N; Fujita T; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2535-8. PubMed ID: 24335365
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
Araki K; Ishida N; Horii R; Takahashi S; Akiyama F; Ito Y; Ohno S
Expert Opin Pharmacother; 2015; 16(17):2561-8. PubMed ID: 26558799
[TBL] [Abstract][Full Text] [Related]
8. Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.
Poggio F; Lambertini M; Blondeaux E; Vaglica M; Levaggi A; Pronzato P; Del Mastro L
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1153-61. PubMed ID: 27545815
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
12. Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
Koi Y; Koga C; Akiyoshi S; Masuda T; Ijichi H; Nakamura Y; Ishida M; Ohno S; Tokunaga E
Anticancer Res; 2018 Mar; 38(3):1579-1584. PubMed ID: 29491088
[TBL] [Abstract][Full Text] [Related]
13. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer.
Gevorgyan A; Bregni G; Galli G; Ganzinelli M; Martinetti A; Lo Vullo S; Mariani L; Festinese F; Sottotetti E; de Braud F; Di Cosimo S
Tumori; 2016 Aug; 102(4):e11-4. PubMed ID: 27174629
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
Catania C; Ascione G; Adamoli L; De Pas T; Medici M; Franceschelli L; Verri E; Magni E; Sanna G; Torrisi R; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2007 Nov; 106(1):97-103. PubMed ID: 17260095
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
Curr Med Res Opin; 2018 Jan; 34(1):49-54. PubMed ID: 29095648
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
[TBL] [Abstract][Full Text] [Related]
19. Nursing perspectives on fulvestrant for the treatment of postmenopausal women with metastatic breast cancer.
Litsas G
Clin J Oncol Nurs; 2011 Dec; 15(6):674-81. PubMed ID: 22119979
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
